{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:12:27Z","timestamp":1768263147404,"version":"3.49.0"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2020,9,1]]},"DOI":"10.1001\/jamadermatol.2020.2149","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T16:01:49Z","timestamp":1594828909000},"page":"982","source":"Crossref","is-referenced-by-count":16,"title":["Association of Anti\u2013Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma"],"prefix":"10.1001","volume":"156","author":[{"given":"Ang\u00e9lique","family":"Brunot","sequence":"first","affiliation":[{"name":"Department of Oncology, Comprehensive Cancer Center Eug\u00e8ne Marquis, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Jacques","family":"Grob","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital, Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geraldine","family":"Jeudy","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital, Dijon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florent","family":"Grange","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital, Reims, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Guillot","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora","family":"Kramkimel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital, APHP Cochin, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Mortier","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital, Lille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannick","family":"Le Corre","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital, Angers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois F.","family":"Aubin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital, Besancon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Mansard","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital, Clermont-Ferrand, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9leste","family":"Lebb\u00e9","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital, Assistance Publique Hopitaux Parsiens, Saint-Louis, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Blom","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital, A. Par\u00e9 Hospital, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henri","family":"Montaudie","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital, Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Giacchero","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Comprehensive Cancer Center Lacassagne, Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sorilla","family":"Prey","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital, Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Legoupil","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital, Brest, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Guyot","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital, Avicenne, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Amini-adle","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Granel-Brocard","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital, Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Meyer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Dinulescu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Edeline","sequence":"additional","affiliation":[{"name":"Department of Oncology, Comprehensive Cancer Center Eug\u00e8ne Marquis, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Campillo-Gimenez","sequence":"additional","affiliation":[{"name":"Department of Oncology, Comprehensive Cancer Center Eug\u00e8ne Marquis, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Lesimple","sequence":"additional","affiliation":[{"name":"Department of Oncology, Comprehensive Cancer Center Eug\u00e8ne Marquis, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"4","key":"doi200041r1","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"doi200041r2","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma.","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"doi200041r3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"doi200041r4","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"doi200041r5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti\u2013CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"doi200041r6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"doi200041r7","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma.","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"doi200041r8","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.","volume":"20","author":"Rozeman","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"doi200041r9","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of resuming anti\u2013PD-1 in patients with immune-related adverse events (irAEs) during combined anti\u2013CTLA-4 and anti\u2013PD-1 in metastatic melanoma.","volume":"29","author":"Pollack","year":"2018","journal-title":"Ann Oncol"},{"issue":"2","key":"doi200041r10","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti\u2013PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"doi200041r11","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nm.4321","article-title":"Is autoimmunity the Achilles\u2019 heel of cancer immunotherapy?","volume":"23","author":"June","year":"2017","journal-title":"Nat Med"},{"issue":"4","key":"doi200041r12","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","article-title":"Overall survival in patients with advanced melanoma who received nivolumab versus investigator\u2019s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial.","volume":"36","author":"Larkin","year":"2018","journal-title":"J Clin Oncol"},{"issue":"26","key":"doi200041r13","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"KEYNOTE-006 Investigators. Pembrolizumab versus ipilimumab in advanced melanoma.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"doi200041r14","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients.","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"34","key":"doi200041r15","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1200\/JCO.2013.51.4802","article-title":"Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.","volume":"31","author":"Weber","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2768255\/jamadermatology_brunot_2020_oi_200041_1599598444.40493.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T15:03:58Z","timestamp":1599663838000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2768255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2020.2149","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,1]]}}}